Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOMUN: Neoadjuvant Pembrolizumab in Resectable NSCLC
NCT03197467Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Jun 2018
- Primary completion
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by AIO-Studien. Primary endpoints: Number of Patients Treated in Compliance With Protocol, Tumor Response According to RECIST 1.1 Criteria and 3 more. Started Jun 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03197467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03197467.